• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Laboratory Corporation of America Holdings (Amendment)

    2/13/24 5:08:06 PM ET
    $LH
    Medical Specialities
    Health Care
    Get the next $LH alert in real time by email
    SC 13G/A 1 tv01307-laboratorycorpofamer.htm SCHEDULE 13G/A laboratorycorpofamericaholdings

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.: 13)*

    Name of issuer:  Laboratory Corp of America Holdings

    Title of Class of Securities:  Common Stock

    CUSIP Number:  50540R409

    Date of Event Which Requires Filing of this Statement: December 29, 2023

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  50540R409

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    108,648

    7.  SOLE DISPOSITIVE POWER

    9,382,041

    8.  SHARED DISPOSITIVE POWER

    363,224

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    9,745,265

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    11.48%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    Laboratory Corp of America Holdings

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    358 South Main Street
    Burlington, NC 27215-5837

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    50540R409

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

      (b) Percent of Class:

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  

    (ii)  shared power to vote or direct to vote:  

    (iii)  sole power to dispose of or to direct the disposition of:  

    (iv)  shared power to dispose or to direct the disposition of:  

    Comments:

    The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.  

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

    No one other person's interest in the securities reported herein is more than 5%.

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    Not applicable

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  February 13, 2024

    By /s/ Ashley Grim
    Name: Ashley Grim
    Title:  Head of Global Fund Administration

    Get the next $LH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LH

    DatePrice TargetRatingAnalyst
    7/10/2025$260.00Buy → Hold
    HSBC Securities
    4/2/2025$276.00Buy
    Redburn Atlantic
    3/4/2025$250.00 → $300.00Neutral → Buy
    Citigroup
    1/7/2025$260.00 → $265.00In-line → Outperform
    Evercore ISI
    12/10/2024$265.00 → $275.00Buy
    Jefferies
    10/30/2024Hold → Buy
    HSBC Securities
    10/1/2024$235.00Neutral
    Piper Sandler
    3/25/2024$250.00Hold → Buy
    Argus
    More analyst ratings

    $LH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President & CEO Schechter Adam H sold $2,437,047 worth of shares (8,705 units at $279.96), decreasing direct ownership by 10% to 80,773 units (SEC Form 4)

    4 - LABCORP HOLDINGS INC. (0000920148) (Issuer)

    3/5/26 8:57:09 AM ET
    $LH
    Medical Specialities
    Health Care

    EVP, Corporate Affairs Van Der Vaart Sandra D sold $156,000 worth of shares (548 units at $284.91), decreasing direct ownership by 18% to 2,579 units (SEC Form 4)

    4 - LABCORP HOLDINGS INC. (0000920148) (Issuer)

    3/3/26 10:41:42 AM ET
    $LH
    Medical Specialities
    Health Care

    EVP, Pres of ED, CMO & CSO Caveney Brian J sold $429,458 worth of shares (1,500 units at $286.31), decreasing direct ownership by 5% to 30,107 units (SEC Form 4)

    4 - LABCORP HOLDINGS INC. (0000920148) (Issuer)

    2/26/26 8:25:40 AM ET
    $LH
    Medical Specialities
    Health Care

    $LH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Illumina and Labcorp expand collaboration to broaden access to precision oncology testing

    SAN DIEGO, March 18, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) and Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, today announced an expanded collaboration to advance precision oncology through innovative applications of next-generation sequencing (NGS) solutions across the healthcare ecosystem. Projects are expected to include promoting equitable access to cancer biomarker testing by bringing it closer to patients through new distributed test offerings; generating evidence to facilitate payer coverage; and developing new tests to address areas of unmet need. "By deepening our collaboration, we'll continue to leverage the strengths of our resp

    3/18/26 9:15:00 AM ET
    $ILMN
    $LH
    Medical Specialities
    Health Care

    Middleby Appoints Glenn Eisenberg To Board of Directors

    The Middleby Corporation (NASDAQ:MIDD), a global leader in the foodservice industry, today announced the appointment of Glenn Eisenberg to its Board of Directors, effective March 1. With the addition of Mr. Eisenberg, the Middleby Board expands to twelve members. "We are pleased to welcome Glenn Eisenberg to the Middleby Board. His deep experience will be an immediate asset as we execute our strategic transformation," said Tim FitzGerald, Middleby CEO. "Glenn has a proven 20-year track record of success as a public company CFO and senior operating executive across complex global manufacturing businesses. His expertise in financial discipline, industrial manufacturing, capital allocation,

    3/6/26 7:00:00 AM ET
    $LH
    $LMRI
    $MIDD
    Medical Specialities
    Health Care
    Industrial Machinery/Components
    Industrials

    Labcorp Expands Collaboration with PathAI to Deploy FDA-Cleared Digital Pathology Platform Nationwide

    AISight® Dx will support fully digital workflows and AI-enabled insights across Labcorp's network of anatomic pathology labs and hospital collaborations to improve efficiency, collaboration and patient careBURLINGTON, N.C., Feb. 23, 2026 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, today announced an expanded collaboration with PathAI to deploy AISight® Dx1, an FDA-cleared digital pathology platform, across its national network of anatomic pathology labs and hospital collaborations. The cloud-based technology allows pathologists to view and manage slides digitally and use AI to support key steps in the diagnostic process.

    2/23/26 7:00:00 AM ET
    $LH
    Medical Specialities
    Health Care

    $LH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Labcorp Holdings Inc. downgraded by HSBC Securities with a new price target

    HSBC Securities downgraded Labcorp Holdings Inc. from Buy to Hold and set a new price target of $260.00

    7/10/25 9:03:30 AM ET
    $LH
    Medical Specialities
    Health Care

    Redburn Atlantic initiated coverage on Labcorp Holdings Inc. with a new price target

    Redburn Atlantic initiated coverage of Labcorp Holdings Inc. with a rating of Buy and set a new price target of $276.00

    4/2/25 8:50:29 AM ET
    $LH
    Medical Specialities
    Health Care

    Labcorp Holdings Inc. upgraded by Citigroup with a new price target

    Citigroup upgraded Labcorp Holdings Inc. from Neutral to Buy and set a new price target of $300.00 from $250.00 previously

    3/4/25 7:36:42 AM ET
    $LH
    Medical Specialities
    Health Care

    $LH
    SEC Filings

    View All

    SEC Form 10-K filed by Labcorp Holdings Inc.

    10-K - LABCORP HOLDINGS INC. (0000920148) (Filer)

    2/24/26 1:51:36 PM ET
    $LH
    Medical Specialities
    Health Care

    Labcorp Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - LABCORP HOLDINGS INC. (0000920148) (Filer)

    2/17/26 6:54:50 AM ET
    $LH
    Medical Specialities
    Health Care

    SEC Form 144 filed by Labcorp Holdings Inc.

    144 - LABCORP HOLDINGS INC. (0000920148) (Subject)

    2/9/26 1:30:58 PM ET
    $LH
    Medical Specialities
    Health Care

    $LH
    Financials

    Live finance-specific insights

    View All

    Labcorp Announces 2025 Fourth Quarter and Full Year Results

    Company Provides 2026 GuidanceFinancial results from Operations versus 2024:Revenue: Q4 of $3.52 billion vs $3.33 billion; Full year of $13.95 billion vs $13.01 billionDiluted EPS: Q4 of $1.98 vs $1.70; Full year of $10.46 vs $8.84Adjusted EPS: Q4 of $4.07 vs $3.45; Full year of $16.44 vs $14.57Free Cash Flow: Q4 of $490.3 million vs. $665.1 million; Full year of $1.21 billion vs $1.10 billionProvided Full-Year 2026 Enterprise Revenue, Adjusted EPS and Free Cash Flow guidance:Revenue of $14.61 billion to $14.79 billion; midpoint growth of 5.4%Adjusted EPS of $17.55 to $18.25; midpoint growth of 8.9%Free Cash Flow of $1.24 billion to $1.36 billion; midpoint growth of 7.8%Expanded partnerships

    2/17/26 6:50:00 AM ET
    $LH
    Medical Specialities
    Health Care

    Labcorp to Announce Fourth Quarter Financial Results on February 17, 2026

    BURLINGTON, N.C., Jan. 15, 2026 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE:LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the fourth quarter of 2025 before the market opens on Tuesday, February 17, 2026. The company will host a conference call and webcast beginning at 9 a.m. ET that day to discuss the results. The earnings press release and accompanying financial information will be posted on the Labcorp Investor Relations website. The call will be webcast live on the Labcorp Investor Relations website. Partici

    1/15/26 4:15:00 PM ET
    $LH
    Medical Specialities
    Health Care

    Labcorp Declares Quarterly Dividend

    BURLINGTON, N.C., Jan. 14, 2026 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE:LH), a global leader of innovative and comprehensive laboratory services, announced today that its Board of Directors has declared a cash dividend of $0.72 per share of common stock. The dividend will be payable on March 12, 2026, to stockholders of record as of the close of business on February 27, 2026. About LabcorpLabcorp (NYSE:LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and c

    1/14/26 6:50:00 AM ET
    $LH
    Medical Specialities
    Health Care

    $LH
    Leadership Updates

    Live Leadership Updates

    View All

    Middleby Appoints Glenn Eisenberg To Board of Directors

    The Middleby Corporation (NASDAQ:MIDD), a global leader in the foodservice industry, today announced the appointment of Glenn Eisenberg to its Board of Directors, effective March 1. With the addition of Mr. Eisenberg, the Middleby Board expands to twelve members. "We are pleased to welcome Glenn Eisenberg to the Middleby Board. His deep experience will be an immediate asset as we execute our strategic transformation," said Tim FitzGerald, Middleby CEO. "Glenn has a proven 20-year track record of success as a public company CFO and senior operating executive across complex global manufacturing businesses. His expertise in financial discipline, industrial manufacturing, capital allocation,

    3/6/26 7:00:00 AM ET
    $LH
    $LMRI
    $MIDD
    Medical Specialities
    Health Care
    Industrial Machinery/Components
    Industrials

    Labcorp Appoints John H. Sampson, M.D., Ph.D., to Board of Directors

    BURLINGTON, N.C., Feb. 9, 2026 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, today announced the appointment of John H. Sampson, M.D., Ph.D., MHSc, MBA, to its Board of Directors, effective February 9, 2026. Dr. Sampson serves as vice chancellor for health affairs and dean of the University of Colorado Anschutz School of Medicine at the CU Anschutz medical campus. As a nationally recognized neurosurgeon, physician-scientist and academic leader, Dr. Sampson brings extensive experience spanning clinical care, biomedical r

    2/9/26 8:30:00 AM ET
    $LH
    Medical Specialities
    Health Care

    Labcorp Appoints Victor Bulto to Board of Directors

    Bulto, President, U.S. of Novartis, brings global healthcare leadership and growth track record to support Labcorp's long-term strategy BURLINGTON, N.C., Nov. 24, 2025 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, today announced the appointment of Victor Bulto, a seasoned pharmaceutical executive and member of Novartis' executive leadership team, to its Board of Directors, effective December 1, 2025. Bulto is an accomplished global executive with 25 years of experience in healthcare, and a proven track record of leadin

    11/24/25 8:30:00 AM ET
    $LH
    Medical Specialities
    Health Care

    $LH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Laboratory Corporation of America Holdings (Amendment)

    SC 13G/A - LABORATORY CORP OF AMERICA HOLDINGS (0000920148) (Subject)

    2/13/24 5:08:06 PM ET
    $LH
    Medical Specialities
    Health Care

    SEC Form SC 13D/A filed by Laboratory Corporation of America Holdings (Amendment)

    SC 13D/A - LABORATORY CORP OF AMERICA HOLDINGS (0000920148) (Filed by)

    7/24/23 4:20:26 PM ET
    $LH
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed

    SC 13G/A - LABORATORY CORP OF AMERICA HOLDINGS (0000920148) (Subject)

    2/10/21 11:14:27 AM ET
    $LH
    Medical Specialities
    Health Care